SCHEMBL14927291

SCHEMBL14927291

O=C(c1ccc2nc(-c3ccccc3)oc(=O)c2c1)c1ncc2ccccn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 1/20 0.44
▸ KMT2A Q03164 6/20 0.40
▸ MEN1 O00255 5/20 0.40
▸ ALDH1A1 P00352 4/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ POLB P06746 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ F2 P00734 1/20 0.39
▸ MAPT P10636 4/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MAPK10 P53779 1/20 0.39
▸ RAB9A P51151 4/20 0.38
▸ NPC1 O15118 3/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ HPN P05981 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.37
▸ CHEK1 O14757 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14927300 0.87 ELANE (0.44) ELANEKMT2AMEN1ALDH1A1KDM4E
SCHEMBL692456 0.81 ELANE (0.62) ELANEKMT2AMEN1ALDH1A1KDM4E
SCHEMBL14927302 0.76 HPD (0.46) —
SCHEMBL321784 0.76 ELANE (0.62) ELANEKMT2AMEN1ALDH1A1KDM4E
SCHEMBL327387 0.74 SLC2A1 (0.52) ALDH1A1KDM4ESMN1; SMN2RAB9ACHEK1
SCHEMBL322099 0.74 ELANE (0.59) ELANEKMT2AMEN1ALDH1A1KDM4E
SCHEMBL320811 0.73 MAPT (0.43) ELANEKMT2AMEN1ALDH1A1KDM4E
SCHEMBL28177735 0.73 NTRK1 (0.42) KMT2AMEN1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL321828 0.71 ALDH1A1 (0.41) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL6565079 0.71 MAPT (0.54) ELANEKMT2AMEN1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 — — US disclosed
US-9452164-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2016-09-27 — — US disclosed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 — — US disclosed
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-28 — — US disclosed
US-8759344-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2014-06-24 — — US disclosed
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH ELANE 4582/4885KMT2A 1185/4885MEN1 1810/4885
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives CCNY, UTS2R, WNK2 ELANE 4194/4885KMT2A 847/4885MEN1 1340/4885
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH ELANE 4582/4885KMT2A 1185/4885MEN1 1810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback